105 related articles for article (PubMed ID: 25791453)
1. Synthesis and evaluation of a ligand targeting the somatostatin-2 receptor for drug delivery to neuroendocrine cancers.
Li G; Low PS
Bioorg Med Chem Lett; 2015 Apr; 25(8):1792-1798. PubMed ID: 25791453
[TBL] [Abstract][Full Text] [Related]
2. Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach.
Oron-Herman M; Kirmayer D; Lupp A; Schulz S; Kostenich G; Afargan M
Sci Rep; 2023 Nov; 13(1):20857. PubMed ID: 38012197
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor staining in FFPE sections using a ligand derivative dye as an alternative to immunostaining.
Hasegawa K; Kudoh S; Ito T
PLoS One; 2017; 12(2):e0172030. PubMed ID: 28182792
[TBL] [Abstract][Full Text] [Related]
4. Influence of the Molar Activity of
Pretze M; Michler E; Runge R; Wetzig K; Tietze K; Brandt F; Schultz MK; Kotzerke J
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004470
[TBL] [Abstract][Full Text] [Related]
5. Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy: Erratum.
Clin Nucl Med; 2022 Aug; 47(8):754. PubMed ID: 35797632
[No Abstract] [Full Text] [Related]
6. Octreotide and Octreotide-derived delivery systems.
Fan M; Huang Y; Zhu X; Zheng J; Du M
J Drug Target; 2023 Jul; 31(6):569-584. PubMed ID: 37211679
[TBL] [Abstract][Full Text] [Related]
7. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment.
Si Y; Guan J; Xu Y; Chen K; Kim S; Zhou L; Jaskula-Sztul R; Liu XM
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33187322
[TBL] [Abstract][Full Text] [Related]
8. Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery.
Large DE; Soucy JR; Hebert J; Auguste DT
Adv Ther (Weinh); 2019 Jan; 2(1):. PubMed ID: 38699509
[TBL] [Abstract][Full Text] [Related]
9. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view.
Öberg K
Scand J Gastroenterol; 2015 Jun; 50(6):727-39. PubMed ID: 25855088
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
15. Pegvisomant Treatment in Acromegaly.
Neggers SJ; Muhammad A; van der Lely AJ
Neuroendocrinology; 2016; 103(1):59-65. PubMed ID: 25792221
[TBL] [Abstract][Full Text] [Related]
16. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy?
Lapa C; Linsenmann T; Lückerath K; Samnick S; Herrmann K; Stoffer C; Ernestus RI; Buck AK; Löhr M; Monoranu CM
PLoS One; 2015; 10(3):e0122269. PubMed ID: 25807228
[TBL] [Abstract][Full Text] [Related]
18. mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer.
Shahbaz M; Ruliang F; Xu Z; Benjia L; Cong W; Zhaobin H; Jun N
World J Surg Oncol; 2015 Feb; 13():46. PubMed ID: 25890201
[TBL] [Abstract][Full Text] [Related]
19. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
[TBL] [Abstract][Full Text] [Related]
20. Tuning to the right signal.
Huising MO
Diabetologia; 2015 Jun; 58(6):1146-8. PubMed ID: 25810040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
